Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Erwinia amylovora is a Gram-negative phytopathogenic bacterium and the etiological agent of fire blight, a highly destructive disease affecting pome fruit trees such as Malus (apple) and Pyrus (pear) [1, 2]. It is characterized by its ability to rapidly colonize plant tissues, leading to necrosis and a scorched appearance of blossoms, leaves, and twigs [2]. The primary virulence factors include the Type III secretion system (T3SS), which translocates DspA/E effectors to suppress host hypersensitive responses, and the synthesis of the exopolysaccharide amylovoran, which facilitates vascular plugging and biofilm development [3]. While traditionally managed with antibiotics like streptomycin and kasugamycin, the emergence of resistant strains has shifted focus toward developing small-molecule inhibitors of T3SS or amylovoran biosynthesis [4, 5]. Understanding the molecular mechanisms of E. amylovora is critical for developing targeted agricultural therapeutics that mitigate crop loss without promoting broad-spectrum environmental resistance [5].
The primary mechanisms of action for agents targeting Erwinia amylovora involve the inhibition of bacterial protein synthesis; streptomycin and kasugamycin bind to the 30S ribosomal subunit, while oxytetracycline binds to the 30S/50S subunits to prevent aminoacyl-tRNA attachment [4]. Copper-based bactericides act through the non-specific denaturation of proteins and disruption of cellular membranes [2]. Additionally, growth regulators like prohexadione-calcium act indirectly by inhibiting the biosynthesis of gibberellins, which alters host physiology to reduce the spread of the infection [5].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Erwinia amylovora (E. amylovora).